BLAINJECTIONINJECTABLE
Approved
May 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
BKEMV (eculizumab-aeeb) by Amgen is complement inhibitors [moa]. Approved for complement inhibitor [epc]. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BKEMV (eculizumab-aeeb) is a monoclonal antibody complement inhibitor approved by the FDA on May 28, 2024, representing a biosimilar or follow-on formulation of an established complement pathway blocker. It is indicated for conditions where complement-mediated inflammation drives disease pathology, treating patients with dysregulated innate immunity.
Growth
Early growth-stage product with moderate competitive pressure (30%) suggests expanding commercial infrastructure and field team opportunities.
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BKEMV positions you in a high-growth complement inhibitor class within a stable, growth-phase product at Amgen. This is a patient-centric rare disease portfolio role with long-term stability, requiring expertise in specialty infusion logistics, managed care negotiation, and HCP education in narrow indication spaces.
Brand Manager
Worked on BKEMV at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.